Pan Tumor Rollover Study

NCT03899155 · readout in 1,102 d

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →. With Exelixis, Novartis, Clovis Oncology, Inc., Janssen Pharmaceuticals.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

1,500estimated

Sites

399

Countries

Argentina, Australia, Austria +35

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2019-08-09

actual

When the study began enrolling

Primary completion

2029-08-25

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-08-25

estimated

The whole study's end, after follow-up

First posted

2019-04-02

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Cancer

Interventions

Drug: Nivolumab — also filed as BMS-936558-01
Drug: Ipilimumab
Drug: Cabozantinib
Drug: Trametinib
Drug: Relatlimab — also filed as BMS-986016-01
Drug: Nivolumab + Relatlimab — also filed as BMS-986213
Drug: Capecitabine
Drug: Bevacizumab
Drug: Temozolomide
Drug: Rucaparib
Drug: Daratumumab
Drug: Regorafinib
Drug: Leucovorin
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Enzalutamide
Drug: Sunitinib
Drug: Pemetrexed
Drug: Pembrolizumab